MDGL Q1 2023 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$78M

Net Income

-$77M

EPS (Diluted)

$-4.23

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$84M

Free Cash Flow

-$84M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$332M

Total Liabilities

$182M

Stockholders' Equity

$150M

Cash & Equivalents

$113M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$78M	-$58M	-36.0%
Net Income	-$77M	-$58M	-33.7%